Does Ruxolitinib, in Comparison to Best Available Therapy (BAT), Improve Pruritis Symptoms in Patients with Polycythemia Vera?: A Systematic Review | Chapter 10 | Medical Research and Its Applications Vol. 9

This systematic review evaluated three randomized controlled trials comparing the efficacy of the Janus kinase inhibitor ruxolitinib in the treatment of polycythemia vera and its reduction of pruritus symptoms in patients with symptomatic polycythemia vera. Polycythemia vera manifests as a myeloproliferative neoplasm associated with diverse symptoms, including aquagenic pruritis. Symptoms associated with polycythemia vera are related to blood hyperviscosity. Most patients can experience a broad range of symptoms including fatigue, pruritis, muscle aches, sweating, shortness of breath, erythromelalgia, and splenomegaly. The rarity and low prevalence of polycythemia vera underscore the importance of this investigation, as an existing standard of care involves a multifaceted approach and significant healthcare costs. Despite advancements in therapeutic options, persistent symptoms and resistance to first-line treatments pose challenges. Ruxolitinib has emerged as a promising intervention, demonstrating clinically significant improvement for patients. This systematic review appraises three randomized controlled trials, shedding light on the efficacy of ruxolitinib and its potential to ameliorate pruritis symptoms in symptomatic patients. Further studies focusing specifically on the longer-term evaluation of ruxolitinib compared to the best available therapy, as it pertains to symptomatic improvement, are warranted to determine whether there is a true statistical significance.

 

Author(s) Details

Zachary Samuel Thorogood

Philadelphia College of Osteopathic Medicine, Philadelphia, PA 19131, USA.

 

Please see the book here:- https://doi.org/10.9734/bpi/mria/v9/965

Elucidating the Role of Next Generation Immune Checkpoint Inhibitors in the Management of Philadelphia Chromosome-Negative Classic Myeloproliferative Neoplasms: A Comprehensive Literature Review | Chapter 7 | Advanced Concepts in Medicine and Medical Research Vol. 9

The Philadelphia deoxyribonucleic acid-negative (Ph-) myeloproliferative neoplasms (MPNs), encompassing essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF), represent a group of continuous and well-documented hematological disorders. These conditions are represented by aberrant increase of one or more hematopoietic cell lineages inside the body’s stem cells, culminating in organomegaly and the rise of constitutional symptoms. A plethora of research has confirmed that the etiology of these diseases is intricately linked to immune order dysregulation and chronic inflammation, two together of which play pivotal acts.Recent advancements in oncological cure, particularly in hematological malignancies, have happened directed towards modalities intend the immune system, the cytokine environment, immunotherapeutic agents, and specialized invulnerable therapies. Immune checkpoints, that are crucial managers of T cell functionality inside the tumor microenvironment (TME), include basic checkpoints such as programmed container death-1 (PD-1)/register cell death ligand-1 (PD-L1), and cytotoxic T-lymphocyte irritant-4 (CTLA-4). Immune checkpoint inhibitor healing (ICIT) revolutionizes cancer treatment by hindering the inhibitory pathways in T cells. Despite the extraordinary clinical realizations of ICIT, intrinsic tumor opposition remains a formidable challenge for oncologists, exhibiting as suboptimal response rates in two together solid tumors and hematological malignancies.A Phase II dispassionate trial (Identifier: NCT02421354) fact-finding the efficacy of nivolumab, a PD-1 blockade power, in patients with post-essential thrombocythemia myelofibrosis, basic myelofibrosis, or post-polycythemia myelofibrosis was initiated but prematurely stopped due to antagonistic events and insufficient productiveness. Concurrently, a multicenter, Phase II, sole-arm open-label study involving pembrolizumab in patients accompanying primary thrombocythemia, post-essential thrombocythemia, or post-polycythemia vera myelofibrosis, who were unavailable for or had previously taken ruxolitinib treatment, was conducted. This study decided that while pembrolizumab administration was not associated accompanying significant adverse occurrences, it failed to evoke meaningful clinical answers, leading to its stop after the initial stage.Taking everything in mind these outcomes, the focus in immunotherapy has shifted towards novel invulnerable checkpoints within the TME, in the way that lymphocyte activation gene-3 (Delay-3), T cell immunoglobulin and mucin domain 3 (TIM-3), T container immunoglobulin and ITIM domain (TIGIT), V-domain immunoglobulin-holding suppressor of T cell activation (View), and human endogenous retrovirus-H long terminal repeat-mixing protein 2 (HHLA2). These are forming the foundation for the future generations of ICIT. The primary objective of this discourse search out highlight and explicate the significance of next-generation ICIT in the circumstances of MPN. Specifically, this article inquires to investigate the potential of monoclonal antibodies as targeted immunotherapy and the incident of vaccines targeting specific MPN epitopes, focusing to enhance tumor-connected immune reactions. It is projected that these immunotherapy-based healing strategies will not only broaden but further refine the treatment range for MPN patients. Preliminary investigations in our workshop have revealed over-verbalization of MDSC and VISTA in MDSC, progenitor, and invulnerable cells, underscoring the necessity for supplementary clinical trials engaging next-generation ICIs in MPN administration.

Author(s) Details:

Ruchi Yadav,
Department of Hematology/Oncology, Brookdale University Hospital Medical Center, Brooklyn, NY 11212, USA.

Narek Hakobyan,
Department of Internal Medicine, Brookdale University Hospital Medical Center, Brooklyn, NY 11212, USA.

Jen C. Wang,
Department of Hematology/Oncology, Brookdale University Hospital Medical Center, Brooklyn, NY 11212, USA.

Please see the link here: https://stm.bookpi.org/ACMMR-V9/article/view/12851

Diagnosis and Management of Chronic BCR-ABL-Positive and BCR-ABL-Negative Myeloproliferative Neoplasms in Elderly Patients: An Approach towards Hematologic Oncology and Public Health | Chapter 16 | Issues and Developments in Medicine and Medical Research Vol. 5

 Background: Chronic myeloproliferative neoplasms (CMN) are the most common chronic leukemias among the elderly in the structure of morbidity by hematologic malignancies with primary bone marrow involvement, characterised in advanced stages by a severe, relapsing evolution and unfavourable prognosis, with negative socioeconomic impact.

Study Goals: To improve hematologic oncology care for older patients with chronic BCR-ABL-positive and BCR-ABL-negative myeloproliferative neoplasms, researchers evaluated diagnosis and management choices in chronic BCR-ABL-positive and BCR-ABL-negative myeloproliferative neoplasms.

Methods and Materials: A clinico-analytical, descriptive, prospective-retrospective investigation was carried out, as well as a narrative evaluation of the relevant international literature. From 1995 to 2021, the Institute of Oncology followed and treated 91 elderly patients with chronic myeloid leukaemia (CML), primary myelofibrosis (PMF), and polycythemia vera (PV). In terms of the impact scale, 29 appropriate primary sources were identified and selected using a rigorous, repeatable, and transparent approach to the topic at hand, followed by data extraction and analysis.

Our study followed up on 34 (37.3%) patients with PMF, 26 (28.6%) patients with CML, and 31 (34.1%) patients with PV who were diagnosed in the older age groups. The age group of 60-69 years old dominated CML (22 cases, or 84.6 percent), PV (25 cases, or 80.6 percent), and PMF (25 cases, or 73.5 percent). Overall survival (OS) was 97.6% and 79.8% in CML patients aged greater than or equal to 60 years treated with tyrosine kinase inhibitors (TKIs), respectively, which was lower than the same indicators in the entirety of CML. The OS in older PV patients was 100% after one year, 93.5 percent after five years, and 76.4 percent after ten years, all of which were lower within 5-10 years than in all PV patients (over one year, 98.6% after five years, and 85.9% after ten years). Despite the fact that patients treated with busulfan had a lower relapse rate than those treated with hydroxycarbamide, there was no significant difference in the OS of elderly PV patients receiving treatment with these anticancer drugs. According to contemporary bibliographic databases, a substantial percentage of patients with CMN suffered reduced work hours, job loss, and medical disability: PMF – 38 percent, 35 percent, 33 percent, and PV – 33 percent, 28 percent, and 15%, respectively.

Conclusions: Because of the development of age-related diseases and vascular events as a result of higher values of leukocytes and platelets, the long-term results of treatment in elderly patients with CMN were shown to be poorer to those in CMN totality. TKI-targeted therapy is still the first-line treatment choice for CML patients aged 60 and up. There was no significant difference in short- and long-term results of chemotherapy with busulfan and hydroxycarbamide in combination with phlebotomy in elderly PV patients, who were completely superior than PMF patients.

Author(S) Details

Vasile Musteata
Discipline of Hematology, “Nicolae Testemitanu” State University of Medicine and Pharmacy, Republic of Moldova and Department of Hematology, Institute of Oncology Chisinau, Republic of Moldova.

Valentina Stratan
Laboratory of Immunology and Molecular Genetics, Institute of Oncology Chisinau, Republic of Moldova.

View Book:- https://stm.bookpi.org/IDMMR-V5/article/view/5591